1. Pink Sheet
  2. >>R&D

Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize

 
• By Emily Hayes

Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.

SC1810_Nobel Award_1094864642_1200.jpg

Inventor of the groundbreaking CTLA-4 checkpoint inhibitor Yervoy, James P. Allison, said he learned he had been awarded the Nobel Prize in Physiology or Medicine, along with PD-L1 pioneer Tasuko Honjo, through a call from his son at 5:30 a.m. on Oct. 1.

The Karolinska Institute's Nobel Assembly announced that day that James Allison, aged 70, of the MD Anderson Cancer Center in Houston, Texas, and Tasuko Honjo, aged 76 and a professor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.